Description

Revumenib 110mg Tablet (LuciRevu) – Uses, Side Effects, Dosage & Price in Pakistan

Revumenib 110mg Tablet (LuciRevu) is a prescription cancer medicine containing revumenib, a targeted treatment known as a menin inhibitor. It is used for certain types of acute leukemia when specific genetic changes are present and the patient meets the treatment criteria. Revumenib treatment requires specialist supervision, laboratory monitoring, and careful assessment of possible side effects.

Patients and caregivers searching for Revumenib 110mg Tablet (LuciRevu) in Pakistan should understand its approved uses, dosage considerations, safety warnings, and the importance of obtaining genuine medicine through a reliable source. Impo Medic provides medicine-related information to help patients and caregivers make informed enquiries about products and their availability.

What Is Revumenib 110mg Tablet (LuciRevu)?

Revumenib is an oral targeted cancer medicine classified as a menin inhibitor. Unlike conventional chemotherapy, which can affect many rapidly dividing cells, targeted medicines act on particular biological processes involved in cancer development.

Revumenib is approved in the United States under the brand name Revuforj for specific cases of relapsed or refractory acute leukemia associated with a KMT2A gene translocation, and for certain cases of acute myeloid leukemia (AML) with a susceptible NPM1 mutation when no satisfactory alternative treatment options are available. The treatment decision depends on the patient’s diagnosis and appropriate genetic testing.

The name LuciRevu is the product name provided for this article. The exact manufacturer, packaging authenticity, and regulatory status of this specific product should be confirmed before purchase.

Revumenib 110mg Tablet Uses

Revumenib may be prescribed for eligible patients with particular forms of acute leukemia. Its use depends on the leukemia subtype, genetic test results, previous treatments, and the patient’s overall medical condition.

1. Relapsed or Refractory Acute Leukemia With a KMT2A Translocation

Revumenib is indicated for certain patients aged one year and older with acute leukemia that has returned after treatment or has not responded adequately to previous therapy, when testing confirms a KMT2A gene translocation.

A KMT2A translocation can contribute to abnormal blood-cell development. The specialist evaluates the patient’s test results to determine whether revumenib is an appropriate option.

2. Certain Cases of Acute Myeloid Leukemia (AML)

Revumenib is also indicated for eligible adults and children aged one year and older with relapsed or refractory acute myeloid leukemia carrying a susceptible NPM1 mutation, provided they have no satisfactory alternative treatment options.

Not every patient with AML is eligible for this medicine. A hematologist or oncologist must assess the specific mutation and treatment history before prescribing it.

Important: Revumenib is not a general treatment for every type of leukemia or cancer. Its use must be based on the relevant diagnosis and eligibility criteria.

How Does Revumenib Work?

Revumenib blocks the activity of a protein called menin. In certain leukemias, interactions involving menin help maintain abnormal gene activity that prevents immature blood cells from developing normally.

By inhibiting this interaction, revumenib can help restore aspects of normal blood-cell development and support the treatment of leukemia with particular genetic abnormalities.

The medicine does not work for every cancer type. Its potential benefit depends on the leukemia’s biological characteristics and the patient’s response to treatment.

Revumenib 110mg Tablet Dosage and Administration

The dosage of Revumenib 110mg Tablet (LuciRevu) must be determined by a qualified hematologist or oncologist. The 110mg strength does not mean that every patient should take one tablet per dose. The official revumenib dosing schedule varies according to body weight and whether the patient is taking certain medicines that affect revumenib levels.

Depending on the prescribed regimen, the total dose may require different tablet strengths. Patients should never calculate or change their dose independently.

Important administration guidance includes:

• Take the medicine exactly as prescribed by the treating specialist.
• Follow the prescribed schedule consistently.
• The official revumenib label allows administration while fasting or with a low-fat meal, at approximately the same times each day.
• Ask the healthcare professional what to do if a dose is missed or vomiting occurs after a dose.
• Do not crush, split, stop, or adjust tablets unless the treating team or product-specific instructions confirm what is appropriate.
• Do not use another person’s prescription or share this medicine.

Treatment may continue for an extended period if the patient benefits and side effects remain manageable. The treating specialist decides when treatment should be continued, adjusted, interrupted, or stopped.

Revumenib 110mg Tablet Side Effects

Like other targeted cancer medicines, revumenib can cause side effects. Some may be manageable, while others require urgent medical attention.

Commonly Reported Side Effects

Side effects reported with revumenib include:

• Nausea
• Diarrhea or constipation
• Fatigue and weakness
• Reduced appetite
• Swelling or fluid retention
• Muscle or joint pain
• Changes in liver-function blood tests
• Changes in phosphate or potassium levels
• Infections and fever
• Abnormal heart electrical activity detected on an ECG

The severity and combination of side effects vary between patients. The treating team may recommend supportive treatment, laboratory tests, or dose adjustments when necessary.

Serious Side Effects Requiring Urgent Attention

Differentiation syndrome: This potentially life-threatening reaction may cause fever, difficulty breathing, low oxygen levels, swelling, rapid weight gain, low blood pressure, fluid around the lungs or heart, or kidney problems. Seek urgent medical care if these symptoms develop during treatment.

QT interval prolongation and serious heart-rhythm problems: Revumenib can affect the heart’s electrical activity and may lead to dangerous rhythm disturbances. Fainting, a racing or irregular heartbeat, severe dizziness, or sudden collapse requires urgent assessment.

Serious infection or bleeding: Patients with leukemia may already have low blood-cell counts or weakened immunity. Fever, unusual bleeding, or signs of a severe infection should be reported promptly.

Do not wait for a routine appointment if a serious reaction is suspected. The official prescribing information contains a boxed warning for differentiation syndrome and QTc prolongation, including torsades de pointes.

Warnings and Precautions

Before starting Revumenib 110mg Tablet (LuciRevu), patients should tell their healthcare team about their medical history and all medicines or supplements they use.

• Heart health: An ECG and electrolyte assessment may be needed before and during treatment.
• Blood tests: The specialist may monitor blood counts, kidney function, liver function, and electrolyte levels.
• Drug interactions: Some medicines can change revumenib levels or increase the risk of heart-rhythm problems.
• Pregnancy: Revumenib may cause harm to an unborn baby. Discuss pregnancy risks and effective contraception with the treating specialist.
• Breastfeeding: Breastfeeding is not recommended during treatment with the approved revumenib product. Ask the specialist when it may be safe to resume.
• Older adults: Additional monitoring may be appropriate because some adverse effects can be more frequent in older patients.
• Children: Treatment in children requires specialist assessment and dosing based on the applicable prescribing instructions.

Never stop or change cancer treatment without consulting the treating team, unless emergency medical professionals direct otherwise.

Revumenib Drug Interactions

Revumenib can interact with medicines that affect the CYP3A4 enzyme, which plays a role in how the body processes the drug. Strong CYP3A4 inhibitors may require a dose adjustment, while strong or moderate CYP3A4 inducers may need to be avoided according to the prescribing information.

Medicines that prolong the QT interval can also increase the risk of heart-rhythm complications. Tell the specialist about all prescription medicines, non-prescription products, vitamins, and herbal supplements before treatment begins.

Do not start or stop another medicine without checking with the oncology team or pharmacist.

Revumenib 110mg Tablet Price in Pakistan and Availability

The price and availability of Revumenib 110mg Tablet (LuciRevu) in Pakistan may vary depending on the supplier, product source, packaging, and import arrangements. A verified current price for this specific product has not been confirmed here, so an amount should not be assumed.

Because revumenib is a specialist cancer medicine, patients and caregivers should confirm the exact strength, manufacturer, sealed packaging, batch details, expiry date, storage requirements, and applicable regulatory documentation before purchase.

Availability of a product should not be taken as proof of its registration or authenticity. Ask the supplier for appropriate documentation and confirm the product with the treating hospital or oncology pharmacist.

How to Buy Revumenib 110mg Tablet

Patients and caregivers can contact Impo Medic to enquire about Revumenib 110mg Tablet (LuciRevu), product details, and potential availability in Pakistan. Before placing an order, confirm the exact product name, strength, manufacturer, and supporting documentation with the supplier and your healthcare professional.

Impo Medic aims to provide clear medicine-related information so that customers can make informed enquiries. Availability, authenticity, and supply should be verified for the specific product before any purchase is completed.

Why Choose Impo Medic?

When looking for specialist medicines, patients need clear product information and careful verification. Impo Medic can be a point of contact for enquiries about medicine names, strengths, and potential supply in Pakistan.

For a product such as Revumenib 110mg Tablet (LuciRevu), customers should verify the source and packaging rather than relying on the product name alone. Always follow the prescribing oncologist’s instructions and obtain professional guidance before using this medicine.

Frequently Asked Questions About Revumenib 110mg Tablet (LuciRevu)

1. What is Revumenib 110mg Tablet used for?

Revumenib is used for certain cases of relapsed or refractory acute leukemia associated with a KMT2A translocation, and certain cases of AML with a susceptible NPM1 mutation when eligibility criteria are met.

2. Is Revumenib 110mg a chemotherapy medicine?

Revumenib is a targeted cancer medicine known as a menin inhibitor. It works through a specific biological pathway involved in certain leukemias rather than acting as conventional chemotherapy.

3. Is 110mg the correct dose for every patient?

No. The 110mg figure identifies the tablet strength. The prescribed total dose depends on factors such as body weight, treatment indication, and interacting medicines. Only the treating specialist can determine the correct regimen.

4. What are the serious side effects of revumenib?

Important risks include differentiation syndrome and QTc prolongation, which can lead to serious heart-rhythm problems. Breathing difficulties, fever with swelling or rapid weight gain, fainting, or an irregular heartbeat require urgent medical assessment.

5. Can Revumenib 110mg Tablet be purchased in Pakistan?

Availability of the specific LuciRevu product must be confirmed with a supplier. Contact Impo Medic for an enquiry, and verify the manufacturer’s details, authenticity, and regulatory documentation before purchase.

6. Can I take revumenib without a specialist?

No. Revumenib requires a confirmed diagnosis, appropriate genetic testing, careful dose selection, and ongoing monitoring by a qualified hematologist or oncologist.